ArticleScientific reports2026
Lipid alterations and endothelial dysfunction are associated with multiple sclerosis pathophysiology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is classically considered a central nervous system (CNS)-restricted immune-mediated disorder; however, increasing evidence suggests that systemic mechanisms may contribute to its pathophysiology. This study examined the relationship between lipid profile alterations and endothelial dysfunction in individuals with MS and their associations with disease severity. Intima-media thickness (IMT) and circulating markers of endothelial activation (E-selectin and P-selectin) were assessed in patients with MS and healthy controls. Serum lipid parameters, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL cholesterol, and triglycerides (TG), were measured. Associations between vascular markers, lipid parameters, and clinical characteristics, including Expanded Disability Status Scale (EDSS) scores and disease duration, were analysed. Compared with controls, MS patients demonstrated significant alterations in lipid profiles that correlated with endothelial dysfunction markers and IMT. Soluble E-selectin, TC, HDL-C, and LDL-C showed discriminatory potential between MS patients and healthy individuals. Notably, IMT values were significantly lower in the MS group than in controls, despite higher body-mass index (BMI) and altered lipid profile, suggesting non-atherosclerotic vascular remodelling. Significant associations were also observed between lipid and endothelial markers and clinical measures, including EDSS scores and disease duration. These findings indicate that MS is accompanied by systemic vascular and lipid alterations that extend beyond the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.